Table 3 Response to various therapies after the first disease progression.
Patient ID | Figure ID | Type | Marker mutation | Treatment | Initiation of new treatment (1) | Assay before new treatment (2) | Assay after new treatment (2) | Response evaluation (2) | PM score of the first assay | PM score of the second assay | MART | Objective response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 2B | type I | L858R | CDDP+PEM | 454 | −1 | 21 | 28 | 15057 | 65 | 0.004 | NE |
6 | S3D | type I | exon 19 deletion | local radiation (brain) | 527 | −20 | 68 | n/a | 9865 | 19738 | 2.000 | radiation |
6 | S3D | type I | exon 19 deletion | CBDCA+nabPTX | 644 | −49 | 15 | 42 | 19738 | 18724 | 0.949 | PD |
7 | S3E | type I | exon 19 deletion | CDDP+PEM | 172 | −1 | 57 | 57 | 2206 | n.d. | 0.000 | PD |
8 | S3F | type I | exon 19 deletion | CDDP+PEM | 209 | −5 | 43 | 93 | n.d. | 572 | 572 | SD |
9 | 3 | type I | exon 19 deletion | local radiation (brain) | 358 | −8 | 17 | n/a | 4461 | 8619 | 1.932 | radiation |
9 | 3 | type I | exon 19 deletion | CBDCA+PEM+BEV | 378 | −3 | 71 | 84 | 8619 | 261 | 0.030 | PR |
9 | 3 | type I | exon 19 deletion | PEM | 504 | −14 | 28 | 56 | n.d. | 1254 | 1254 | PD |
9 | 3 | type I | exon 19 deletion | S1+BEV | 589 | 0 | 98 | 49 | 7171 | 3153 | 0.440 | SD |
9 | 3 | type I | exon 19 deletion | gefitinib | 729 | 0 | 41 | 56 | 464 | 639 | 1.377 | PD |
9 | 3 | type I | exon 19 deletion | AZD9291 | 889 | 0 | 21 | 36 | 31119 | 157 | 0.005 | PR |
9 | 3 | type I | exon 19 deletion | docetaxel | 994 | −84 | 42 | 21 | 157 | 33872 | 216 | PD |
9 | 3 | type I | exon 19 deletion | AMR | 1064 | −28 | 35 | 21 | 33872 | 52361 | 1.546 | PD |
10 | S3G | type I | L858R | gefitinib+GEM | 353 | −28 | 7 | 10 | n.d. | 431 | 431 | PD |
10 | S3G | type I | L858R | gefitinib+PEM | 381 | −7 | 42 | 71 | n.d. | n.d. | n/a | NE |
10 | S3G | type I | L858R | local radiation (illium) | 531 | −45 | 19 | n/a | 326 | 2484 | 7.620 | radiation |
11 | 2C | type I | T790M | CBDCA+nabPTX | 334 | −1 | 28 | 133 | 1797 | 29 | 0.016 | PR |
11 | 2C | type I | T790M | erlotinib | 518 | −30 | 45 | 47 | n.d. | n.d. | n/a | SD |
12 | 2D | type II | exon 19 deletion | erlotinib | 336 | −56 | 28 | 61 | 10176 | 24447 | 2.402 | PD |
14 | 2D | type II | exon 19 deletion | local radiation (bone) | 495 | −18 | 4 | n/a | 13650 | 30448 | 2.231 | radiation |
14 | 2F | type II | exon 19 deletion | CBDCA+PTX+BEV | 510 | −11 | 8 | n/a | 30448 | 1789 | 0.059 | NE |
15 | S3H | type II | L861Q | CDDP+PEM | 363 | −2 | 32 | 76 | 620 | n.d. | 0.002 | PR |
15 | S3H | type II | L861Q | PEM | 489 | −94 | 42 | 30 | n.d. | n.d. | n/a | SD |
